Neurosearch A/s

Abbott Laboratories Corporation

Aniona Aps

Danpet Ab

Saniona A/s

Philip K Ahring

Elsebet Østergaard Nielsen

Dan Peters

Gunnar M Olsen

Tino Dyhring Jørgensen

Lene Teuber

Janus Schreiber Larsen

Naheed Mirza

Elsebet Ostergaard Nielsen

William Dalby Brown

David Tristram Brown

Tino Dyhring Jorgensen

Elsebet Oestergaard Nielsen

Palle Christophersen

Michael R Schrimpf

Kevin B Sippy

Daniel B Timmermann

Simon Feldbaek Nielsen

Simon Feldbæk Nielsen

Tino Dyhring

Bo Skaaning Jensen

Thomas Varming

Søren Peter Olesen

Gurmar M Olsen

Marianne Lerbech Jensen

Tino Dyhring Joergensen

Dorte Strøbaek

Elsebet ØStergaard Nielsen

Janus S Larsen

This invention relates to diazabicyclononyl oxadiazolyl derivatives, which are found to-be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. Arrepresents a pyrrolyl group, optionally substituted with alkyl or halo-alkyl. 

Diazabicyclononyl oxadiazole compounds and their use as nicotinic acetylcholine receptor modulators

The present application discloses novel benzimidazole derivatives and their use as modulators of the GABAreceptor complex. In other aspects the application discloses the use of these compounds, in a method for therapy and to pharmaceutical compositions comprising these compounds.

[object Object]

Benzimidazole derivatives, pharmaceutical compositions containing them, and methods of treatment therewith involving modulation of the GABAreceptor complex. The compounds have the formula I: wherein the variables are as described in the specification. The compounds are useful in the treatment of central nervous system diseases and disorders which are responsive to modulation of the GABAreceptor complex, and in particular for combating anxiety and related diseases.

This invention relates to novel imidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAreceptor complex, and in particular for combating anxiety and related diseases.

Imidazole derivatives for the treatment of anxiety and related diseases

This invention relates to novel benzimidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAreceptor complex, and in particular for combating anxiety and related diseases.

This invention relates to novel benzimidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders which are responsive to modulation of the GABAreceptor complex, and in particular for combating anxiety and related diseases.

This invention relates to novel imidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are of the general formula (I) and include any of its stereoisomers, any mixture of its stereoisomers, and pharmaceutically acceptable salts thereof. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAreceptor complex, and in particular for combating anxiety and related diseases. 

This invention relates to novel quinuclidine derivatives and their use as pharmaceuticals. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

Quinuclidine derivatives and their pharmaceutical use

This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. 

Diazabicyclic aryl derivatives

Azacyclic ethynyl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

Azacyclic ethynyl derivatives

This invention relates to novel azacyclic ethynyl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

This invention relates to novel 3-substituted quinuclidine derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

Growing community of inventors

Bagsværd, Denmark

Philip K Ahring